Arbutus Biopharma is a clinical-stage biopharmaceutical company utilizing its virology expertise to develop therapeutics that target specific viral diseases. Co.'s focus areas include Hepatitis B virus (HBV), SARS-CoV-2 and other coronaviruses. Co.'s product pipeline consists of the following programs: GalNAc RNAi, which is a subcutaneously-delivered RNA interference therapeutic targeted to hepatocytes; Oral Capsid Inhibitor, which is a capsid inhibitor; Oral PD-L1 Inhibitor, which is an oral PD-L1 inhibitor that has the potential to reawaken patients' HBV-specific immune response; and Oral HBV RNA Destabilizer, which is is Co.'s oral HBV specific RNA destabilizer. The ABUS YTD return is shown above.
The YTD Return on the ABUS YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether ABUS YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ABUS YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|